AlzeCure Pharma AB (OSTO:ALZCUR) Current Accrued Expense : kr0.00 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AlzeCure Pharma AB Current Accrued Expense?

AlzeCure Pharma AB's Current Accrued Expense for the quarter that ended in Jun. 2024 was kr0.00 Mil.

AlzeCure Pharma AB Current Accrued Expense Historical Data

The historical data trend for AlzeCure Pharma AB's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzeCure Pharma AB Current Accrued Expense Chart

AlzeCure Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

AlzeCure Pharma AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

AlzeCure Pharma AB Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

AlzeCure Pharma AB Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlzeCure Pharma AB (OSTO:ALZCUR) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

AC6:Germany

Address

Halsovagen 7, Huddinge, SWE, SE 141 57

Website

https://www.alzecurepharma.se

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.

AlzeCure Pharma AB Headlines

No Headlines